A coating for an expandable portion of a catheter comprising a lipophilic matrix and a plurality of micro-reservoirs dispersed in the lipophilic matrix is disclosed. The plurality of micro-reservoirs comprises an active agent. A coating formulation and a method for forming the coating are also disclosed. A catheter comprising the coating on the expandable portion and a method for treating a condition are also provided.

The present invention relates to a therapeutic compound comprising: an agent that inhibits the activity of at least one gene selected from the group consisting of MAF, MEOX2, SIX2 and homologues thereof having at least 50% identity with said genes and/or an agent that enhances the activity of at least one gene selected from the group consisting of CREB5, E2F1, EGR2, HIC1, IRF7, JUN, MYC, SRF, STAT4, TCF4, FOXS1, GLI1, SOX9 and homologues thereof having at least 50% identity with said gene for use in the treatment of wounds, preferably chronic wounds.

Devices and methods for treating ischemia and reperfusion injury (IRI) are configured for sustained-release of anti-proliferative drug into the wall of a blood vessel (to prevent in-stent stenosis), and for sustained-release of leptin antagonist into the lumen to be carried by the blood and be uptaken by tissue cells that were subjected to IRI.

The present disclosure is directed to intracameral implants for treating and/or preventing corneal disorders, diseases, and/or conditions, such as corneal endothelial dystrophies. The intracameral implants can be configured to provide a sustained release of a therapeutic agent, such as a Rho kinase inhibitor, for a prolonged period of time. The intracameral implants can include a non-bioresorbable anchor or a bioresorbable matrix.

The present disclosure describes the use of immune modulators to promote nerve growth and regeneration, particularly in the context of nerve deficit stemming from trauma and disease. In particular, the disclosure provides for the use of of CXCR4 antagonsists, STAT3 activators, and an agent that increase nitric oxide, alone or in combination, to treat nerve deficit conditions.

A cardiovascular graft is provided with highly reduced thrombogenicity. The cardiovascular graft is an electrospun non-woven mesh produced from supramolecular polymers with large diameter fibers. The cardiovascular graft can be implemented as a vascular graft into the human body to allow vascular bypass/reconstruction, or repeated venous access for dialysis treatment, as well as other disorders of small-diameter blood vessels.

The present invention describes and claims pharmaceutical compositions in gel form for use in the treatment of intervertebral disc degeneration, in particular the forms of dehydration and emptying of the nucleus pulposus known as black disc disease. These compositions comprise a hyaluronic acid derivative which forms hydrogels with precise rheological characteristics that make it ideal for filling the nucleus pulposus.

Methods and devices for the repair of articular tissue using collagen material are provided. Compositions of collagen material and related kits are also provided.

Provided are methods for improving cell-based therapies by co-administration with an agent that increases the production and or levels of epoxygenated fatty acids, as well as kits, stents and patches for co-administering stem cells with an agent that increases the production and/or levels of epoxygenated fatty acids.

A device for coating a stent, including a holder for the stent, a spraying unit comprising a spray mandrel and an air nozzle. The spray mandrel, the air nozzle and the holder are configured and disposed relative to each other such that the spray mandrel projects from one side into the stent during coating and the air nozzle projects into the stent from the opposing side. A method for coating a stent employs the device. Stents that can be obtained according to the method.